Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

Journal of Clinical Pharmacology

Volumn 55, Issue 5, 2015, Pages 497-504

  Kapitza, Christoph ^a   Nosek, Leszek ^a   Jensen, Lene ^b   Hartvig, Helle ^b   Jensen, Christine B ^b   Flint, Anne ^b  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

ethinylestradiol; GLP 1; levonorgestrel; once weekly; semaglutide; type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SEMAGLUTIDE; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; ETHINYLESTRADIOL; GLUCAGON LIKE PEPTIDE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL DISTENSION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOEQUIVALENCE; BODY MASS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; KINESIOTHERAPY; MAXIMUM PLASMA CONCENTRATION; MENOPAUSAL SYNDROME; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; POSTMENOPAUSE; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; AGED; BLOOD; DRUG INTERACTION; HALF LIFE TIME; METABOLIC CLEARANCE RATE; MIDDLE AGED;

AGED; AREA UNDER CURVE; BLOOD GLUCOSE; CONTRACEPTIVES, ORAL, COMBINED; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; GLUCAGON-LIKE PEPTIDES; HALF-LIFE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LEVONORGESTREL; METABOLIC CLEARANCE RATE; MIDDLE AGED; POSTMENOPAUSE;

EID: 84926012859     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.443     Document Type: Article

References (31)

1. Drucker DJ, Nauck MA,. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368 (9548): 1696-1705.
2. Flint A, Raben A, Astrup A, Holst JJ,. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998; 101 (3): 515-520.
3. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 1999; 23 (3): 304-311.
4. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA,. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996; 81 (1): 327-332.
5. Pratley RE, Gilbert M,. Targeting incretins in Type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud. 2008; 5 (2): 73-94.
6. Garber AJ,. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus. J Am Osteopath Assoc. 2011; 111 (7 Suppl 5): S20-S30.
7. Martin JH, Deacon CF, Gorrell MD, Prins JB,. Incretin-based therapies-review of the physiology, pharmacology and emerging clinical experience. Intern Med J. 2011; 41 (4): 299-307.
8. Koliaki C, Doupis J,. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2011; 2 (2): 101-121.
9. Deacon CF,. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag. 2009; 5 (1): 199-211.
10. Drucker DJ, Dritselis A, Kirkpatrick P,. Liraglutide. Nat Rev Drug Discov. 2010; 9 (4): 267-268.
11. Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013; 37 (11): 1443-1451.
12. Nauck MA, Petrie JR, Sesti G,. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes. Diabetologia. 2012; 55 (Suppl 1): S7(2-OP).
13. Gotfredsen CF, Molck AM, Thorup I, et al. The human GLP-1 analogs liraglutide and semaglutide: Absence of histopathological effects on the pancreas in nonhuman primates. Diabetes. 2014; 63 (7): 2486-2497.
14. Novo Nordisk.;1; Data on file, 2013.
15. Rhoda Lee C,. Drug interactions and hormonal contraception. Trends Urol. Gynecol Sexual Health. 2009; 14 (3): 23-26.
16. Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M,. Treatment with liraglutide-a once-daily GLP-1 analog-does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol. 2011; 51 (12): 1696-1703.
17. Tzefos M, Harris K, Brackett A,. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother. 2012; 46 (1): 68-78.
18. Kothare PA, Seger ME, Northrup J, Mace K, Mitchell MI, Linnebjerg H,. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. BMC Clin Pharmacol. 2012; 12: 8.
19. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use,. ICH Harmonised Tripartite Guideline for Good Clinical Practice E6 (R1). http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf.
20. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington 2002; and Note of Clarification on Paragraph 30 by the WMA General assembly, Tokyo 2004. http://www.wma.net/en/30publications/10policies/b3/index.html.
21. US Food and Drug Administration (FDA),. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf.
22. European Medicines Agency (EMA),. Guideline on the Investigation of Drug Interactions. CPMP/EWP/560/95/Rev. 1 Corr, June 21, 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf.
23. American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005; 28 (5): 1245-1249.
24. Temple R,. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006; 15 (4): 241-243.
25. Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E,. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012; 124 (6): 55-72.
26. Kapitza C, Flint A, Hindsberger C, Zdravkovic M,. The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol. Diabetes Care. 2008; 57 (suppl 1): A593.
27. Blode H, Schurmann R, Benda N,. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone. Contraception. 2008; 77 (3): 171-176.
28. Nauck MA, Petrie JR, Sesti G, et al. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes. EASD. 2012. Oral presentation 2 (Trial: NN9535-1821).
29. Meier JJ,. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012; 8 (12): 728-742.
30. Lando HM, Alattar M, Dua AP,. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract. 2012; 18 (4): 472-477.
31. Summary of Product Characteristics. Microgynon® 30. http://www.medicines.org.uk/emc/medicine/1827/spc.